UK Begins COVID-19 Vaccine Candidate's Rolling-Review

Moderna, Inc. announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) has started the rolling review process of mRNA-1273, the Company’s vaccine candidate against COVID-19.

This rolling review process allows the MHRA to begin its independent assessment on mRNA-1273 using the information submitted by Moderna and accept new evidence as it becomes available until the application is deemed complete.

Stéphane Bancel, CEO of Moderna, stated in a press release issued on October 27, 2020: “This is a great example of what’s being done to support efforts to deliver a safe and effective vaccine to UK citizens as safely and efficiently as possible.”